(firstQuint)Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer.

 Phase I trail will be conducted to determine the MTD and safety of M2ES(administered intravenous infusion on Days 1,8,15,21of a 28-day cycle) in combination with gemcitabine (1000 m/m2).

 Gemcitabine will be administered as an intravenous infusion on Days 1, 8, and 15 of each 28-day cycle,at the same time determine the safety and efficiency of this combined regime.

.

 Study With M2ES and Gemcitabine for Patients With Advanced Pancreatic Cancer@highlight

Phase I trail will be conducted to evaluate the safety of M2ES in combination with gemcitabine in locally advanced or metastatic pancreatic cancer.

